Reaching the brain: Advances in optic nerve regeneration.
In Exp Neurol, Jan 2016
More recently, some degree of regeneration has been achieved through the optic nerve itself by factors associated with intraocular inflammation (oncomodulin) or by altering levels of particular transcription factors (Klf-4, -9, c-myc), cell-intrinsic suppressors of axon growth (PTEN, SOCS3), receptors to cell-extrinsic inhibitors of axon growth (Nogo receptor, LAR, PTP-σ) or the intracellular signaling pathway activated by these receptors (RhoA).
Targeted Therapies in Triple-Negative Breast Cancer.
Heidelberg, Germany. In Breast Care (basel), Jul 2015
Currently, bevacizumab, a monoclonal anti-vascular endothelial growth factor (VEGF)-A antibody, is the only targeted agent with an approval for the therapy of metastatic breast cancer, but does not provide a specific benefit in the TNBC subtype.
Pasireotide in Acromegaly: A Review.
Auckland, New Zealand. In Drugs, Jun 2015
Pasireotide (Signifor(®), Signifor(®) LAR) is a somatostatin analogue recently approved for the treatment of acromegaly.
[Recent advances in allergic rhinitis].
In Lin Chuang Er Bi Yan Hou Ke Za Zhi, Feb 2015
Current studies have demonstrated local allergic rhinitis (LAR) that patients with both sug- gestive symptoms of AR and a negative diagnostic test for atopy may have local allergic inflammation is a prevalent entity in patients evaluated with rhinitis, but further research remains needed.